What affects kidney cancer prognosis — the factors your team actually weighs

Stage carries the most weight. Stage describes where the cancer has actually reached: still inside the kidney, grown into the surrounding fat or the renal vein, into lymph nodes, or to another organ. Nothing else on the report changes the outlook as much. That said, stage is never read alone. Grade, the tumour subtype, the size, whether it was removed completely and what else the pathologist saw all shift the picture at any given stage, and your own health and kidney function matter as well. Two people with the same stage can have genuinely different outlooks once the rest is taken into account, which is why your team weighs them together rather than quoting you a single figure.

Yes, and in a fairly direct way, because size is one of the things that decides the stage in the first place. As a group, smaller tumours confined to the kidney are found earlier, are more often removed completely, and come back less often than larger ones. Size also influences whether the kidney can be spared and whether active surveillance is reasonable for a very small tumour. What size cannot do is override everything else. A small tumour with high-grade or sarcomatoid features is watched more closely than its size alone would suggest, and a larger tumour that is still contained within the kidney and fully removed can do well. Size is one input, weighed with the rest.

It can, and this is one of the most useful things to understand. A prognosis is an estimate made from the information available on a given day, not a fixed sentence handed down at diagnosis. It is revised when surgery gives a fuller pathology picture than the biopsy did, when the first surveillance scans come back clear, when years pass without recurrence, or when advanced disease responds to systemic treatment. It can also move the other way. That is exactly why follow-up matters: the point of NCCN-based surveillance is to keep the picture current, so that decisions are made on where things stand now rather than on what was said at the beginning.

Yes. Renal cell carcinoma is not one disease, and the subtype named on your pathology report matters. Clear cell is the most common and is the type most of the research and most systemic treatment options were built around. Papillary and chromophobe behave differently from it and from each other, and chromophobe is not routinely graded with the same system because its cells look irregular in a way that does not carry the same meaning. Some rarer subtypes are recognised as more aggressive and are managed accordingly. Subtype also shapes which systemic treatment classes are considered if the disease ever becomes advanced, so it is a line on the report worth asking about specifically.

IMDC risk is a grouping used when kidney cancer has already spread, and it deliberately does not use the grade or the stage. It is built from clinical and blood-test factors: how well you are functioning day to day, how long it has been between diagnosis and needing systemic treatment, and a small set of blood results including haemoglobin, calcium, platelets and neutrophils. Those are combined to place someone in a favourable, intermediate or poor risk group. It matters because it is one of the things that guides which class of systemic treatment is discussed first, and it gives a more realistic sense of the outlook in advanced disease than the original pathology report does.

You cannot change the biology of the tumour, and no diet or supplement will. What you can influence is real, though. Stopping smoking, keeping blood pressure controlled and protecting the kidney function you have left all support the treatment plan and reduce the other risks that come alongside kidney disease. Attending every surveillance scan matters more than most people expect, because a recurrence found early is far more treatable than one found late. Reporting new symptoms promptly rather than waiting for the next appointment does the same job. Bring anything you are taking, including supplements, to your oncologist rather than adding it alongside treatment unmentioned.